Immunocore Holdings Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $53.87
- Today's High:
- $56.22
- Open Price:
- $56.09
- 52W Low:
- $40.77
- 52W High:
- $69.055
- Prev. Close:
- $55.69
- Volume:
- 180433
Company Statistics
- Market Cap.:
- $2.77 billion
- Book Value:
- 5.665
- Revenue TTM:
- $181.57 million
- Operating Margin TTM:
- -27.16%
- Gross Profit TTM:
- $54.11 million
- Profit Margin:
- -27.4%
- Return on Assets TTM:
- -8.38%
- Return on Equity TTM:
- -22.51%
Company Profile
Immunocore Holdings Ltd had its IPO on 2021-02-05 under the ticker symbol IMCR.
The company operates in the Healthcare sector and Biotechnology industry. Immunocore Holdings Ltd has a staff strength of 408 employees.
Stock update
Shares of Immunocore Holdings Ltd opened at $56.09 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $53.87 - $56.22, and closed at $54.02.
This is a -3% slip from the previous day's closing price.
A total volume of 180,433 shares were traded at the close of the day’s session.
In the last one week, shares of Immunocore Holdings Ltd have slipped by -5.67%.
Immunocore Holdings Ltd's Key Ratios
Immunocore Holdings Ltd has a market cap of $2.77 billion, indicating a price to book ratio of 8.1327 and a price to sales ratio of 27.8339.
In the last 12-months Immunocore Holdings Ltd’s revenue was $181.57 million with a gross profit of $54.11 million and an EBITDA of $-45729000. The EBITDA ratio measures Immunocore Holdings Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immunocore Holdings Ltd’s operating margin was -27.16% while its return on assets stood at -8.38% with a return of equity of -22.51%.
In Q2, Immunocore Holdings Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 49.3%.
Immunocore Holdings Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immunocore Holdings Ltd’s profitability.
Immunocore Holdings Ltd stock is trading at a EV to sales ratio of 25.3649 and a EV to EBITDA ratio of -54.1877. Its price to sales ratio in the trailing 12-months stood at 27.8339.
Immunocore Holdings Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $440.36 million
- Total Liabilities
- $92.29 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $768000
- Dividend Payout Ratio
- 0%
Immunocore Holdings Ltd ended 2024 with $440.36 million in total assets and $0 in total liabilities. Its intangible assets were valued at $440.36 million while shareholder equity stood at $277.27 million.
Immunocore Holdings Ltd ended 2024 with $0 in deferred long-term liabilities, $92.29 million in other current liabilities, 98000.00 in common stock, $-292027000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $342.34 million and cash and short-term investments were $342.34 million. The company’s total short-term debt was $2,504,000 while long-term debt stood at $37.12 million.
Immunocore Holdings Ltd’s total current assets stands at $395.06 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $50.82 million compared to accounts payable of $13.99 million and inventory worth $1.89 million.
In 2024, Immunocore Holdings Ltd's operating cash flow was $0 while its capital expenditure stood at $768000.
Comparatively, Immunocore Holdings Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $54.02
- 52-Week High
- $69.055
- 52-Week Low
- $40.77
- Analyst Target Price
- $81.03
Immunocore Holdings Ltd stock is currently trading at $54.02 per share. It touched a 52-week high of $69.055 and a 52-week low of $69.055. Analysts tracking the stock have a 12-month average target price of $81.03.
Its 50-day moving average was $61.14 and 200-day moving average was $58.11 The short ratio stood at 14.24 indicating a short percent outstanding of 0%.
Around 1459.3% of the company’s stock are held by insiders while 7343.2% are held by institutions.
Frequently Asked Questions About Immunocore Holdings Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.